Morgan Stanley upgrades Afya stock rating on valuation despite merger concerns

Morgan Stanley upgraded Afya to Equalweight from Underweight but cut its price target to $12.60 from $15.00, citing valuation that already reflects business challenges and continued caution about seat maturation and structural trends. Afya trades at $10.50; the article cites a 2027 P/E of 6.1x, a 64% gross margin and a 28% free-cash-flow yield. Separately, Q2 2026 revenue rose 6% year over year to BRL 972 million, while adjusted EBITDA margins narrowed; Afya returned BRL 448 million through dividends and repurchases.

Analysis

The key question is whether low valuation reflects temporary skepticism or a lower durable earnings base. A 2027 P/E can look optically cheap while seat maturation slows the earnings denominator; monitor enrollment, seat utilization and tuition realization rather than relying on the multiple alone. Margin pressure from investment in adjacent offerings matters because growth that fails to earn adequate returns can weaken the case for a re-rating.

Capital returns are a second-order risk: distributions and repurchases above internally generated equity cash flow may support near-term per-share results, but could reduce flexibility to fund growth or absorb weaker enrollment. Verify cash-flow definitions, balance-sheet cash and the pace of returns before treating the cited FCF yield as sustainably distributable. For a U.S.-listed investor, BRL earnings also create FX translation risk that can offset local operating progress.

The merger case appears especially sensitive to execution: if incremental value is modest, integration costs or management distraction could consume the expected benefit, while standalone operations may retain more strategic flexibility. Over the next 1–3 months, the most useful catalyst is evidence on margins and seat maturation in reported results; over 6–18 months, enrollment economics and the returns on new education offerings determine whether the discount is deserved. The analyst-rating divergence is not itself proof of a consensus re-rating. A stronger downside scenario is persistent margin erosion plus weaker seat economics; the thesis improves if growth investments stabilize margins without relying on cash returns.

Key Decisions for Investors

• Avoid chasing a valuation-only rebound. Consider a small, staged long in AFYA only after reported enrollment/seat-utilization trends and EBITDA margins stabilize; reassess if margins continue to contract or enrollment economics deteriorate.
• Treat the reported cash-flow yield as a verification item, not a distributable-yield assumption. Before sizing a position, check free cash flow to equity after growth investment, cash balances, and whether buybacks/dividends remain covered without weakening the balance sheet.
• Track the next results for organic growth, margin progression and returns on continuing-education and medical-practice investments. These are more relevant re-rating catalysts than additional broker upgrades.
• Keep the merger thesis separate from the standalone valuation: monitor disclosed integration costs and realized synergies. If execution costs rise without measurable operating benefits, reduce exposure; if benefits materialize while standalone seat economics hold, the risk/reward improves.